Have any insiders bought or sold RGC stock since the June 2025 forward stock split?

Regarding insider trading activity for Regencell Bioscience Holdings Limited (RGC) since its June 2025 forward stock split, Fintel's analysis of SEC filings indicates a specific regulatory status that impacts the public disclosure of such transactions.

Regencell Bioscience Holdings Limited, as a foreign private issuer, is not subject to the same insider reporting requirements as U.S. domestic companies. Specifically, the company's Form 20-F filing for the fiscal year ended June 30, 2025, states that "directors and executive officers will not be required to report equity holdings under Section 16 of the Exchange Act and will not be subject to the insider short-swing profit disclosure and recovery regime."1

This means that while insiders may still engage in buying or selling RGC stock, these transactions are not publicly disclosed through the standard Section 16 filings that Fintel tracks for most U.S.-listed companies. Consequently, there is no publicly available record of insider buying or selling activity for RGC through these typical channels since the 38-for-one forward stock split, which was effected on June 13, 2025.1

Investors seeking to understand ownership changes for RGC would typically look at institutional ownership filings (such as 13F reports) rather than individual insider transactions. Fintel's platform for RGC (NasdaqCM) provides an overview of institutional owners and their holdings.2